In addition, and as previously reported, there was no difference in survival for PMR patients comparing those with PAD with those without PAD (P = 0.16).
Ninety-three (64%) patients were alive without PAD, 13 (9%) alive with PAD, 10 (7%) dead with PAD, and 30 (21%) dead without PAD.
Tungsten levels in urine were 49% higher in subjects with PAD than in those without PAD.
Cadmium levels in urine were 36% higher in subjects with PAD than in those without PAD.
Compared withT2DM patients without PAD, BNP levels were markedly higher in patients with PAD (p = 0.001).
Nevertheless, as suggested by prior research [ 17], patients with PAD reported significantly more work-related impairments than those without PAD, even after accounting for other demographic and health characteristics.
Within each country, those with PAD reported significantly lower mean health utilities than those without PAD; the unadjusted decrease in utilities, i.e., the disutility ranged from 0.07 to 0.13.
People with lower extremity peripheral artery disease (PAD) have greater functional impairment and faster functional decline than those without PAD.
Individuals with PAD had a significantly lower fetuin-A level compared with individuals without PAD (269.3 vs. 293.4, P < 0.001).
A large prospective study found that men with prevalent PAD had an increased rate of hip bone loss compared with men without PAD (-0.6% vs -0.3%, P < 0.001) [ 2].
When stratifying patients according to the presence or absence of PAD, significantly (p < 0.001) worse healing rates were observed in patients with than in those without PAD (69% vs 84%, respectively).
